NetScout Systems, Inc. (NTCT) At $27.65 Forms Bottom; Intercept Pharmaceuticals, Inc. (ICPT) Had 12 Bulls

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals has $423 highest and $45.0 lowest target. $152.22’s average target is 130.11% above currents $66.15 stock price. Intercept Pharmaceuticals had 74 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Market Perform” rating by JMP Securities on Wednesday, October 4. The firm has “Buy” rating given on Monday, July 31 by Oppenheimer. The rating was maintained by Cowen & Co with “Buy” on Monday, June 12. The firm has “Buy” rating given on Tuesday, June 13 by Wedbush. Vetr upgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Tuesday, September 22. Vetr has “Strong-Buy” rating and $207.80 target. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Underperform” rating by Bank of America on Friday, October 13. As per Wednesday, June 1, the company rating was maintained by Wedbush. Wells Fargo maintained it with “Hold” rating and $57.0 target in Tuesday, February 13 report. On Wednesday, October 28 the stock rating was downgraded by Bank of America to “Underperform”. The firm has “Outperform” rating by Wedbush given on Wednesday, February 24. See Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) latest ratings:

17/04/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $256 New Target: $203 Maintain
15/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $152 New Target: $155 Maintain
13/02/2018 Broker: Wells Fargo Rating: Hold New Target: $57.0 Maintain
12/02/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
07/02/2018 Broker: Goldman Sachs Rating: Sell New Target: $45.0 Downgrade
01/02/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
01/02/2018 Broker: Deutsche Bank Rating: Buy New Target: $106.0
25/01/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain
22/01/2018 Broker: Credit Suisse Rating: Buy New Target: $167.0 Maintain
13/12/2017 Broker: Deutsche Bank Rating: Buy New Target: $106 Initiates Coverage On

NetScout Systems, Inc. (NTCT) formed multiple bottom with $26.82 target or 3.00% below today’s $27.65 share price. NetScout Systems, Inc. (NTCT) has $2.41B valuation. The stock decreased 0.72% or $0.2 during the last trading session, reaching $27.65. About 788,079 shares traded. NetScout Systems, Inc. (NASDAQ:NTCT) has declined 32.32% since April 26, 2017 and is downtrending. It has underperformed by 43.87% the S&P500.

The stock increased 0.56% or $0.37 during the last trading session, reaching $66.15. About 600,602 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 26, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.02, from 1.33 in 2017Q3. It is negative, as 19 investors sold Intercept Pharmaceuticals, Inc. shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. Emerald Advisers Inc Pa owns 162,560 shares or 0.37% of their US portfolio. Fifth Third Bank & Trust accumulated 0% or 736 shares. Axa owns 24,632 shares. Eulav Asset Management reported 66,000 shares. D E Shaw Co, New York-based fund reported 22,232 shares. Emerald Mutual Fund Advisers Tru owns 115,679 shares. Royal Comml Bank Of Canada holds 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 94,926 shares. Federated Pa, a Pennsylvania-based fund reported 732 shares. Invesco owns 10,766 shares. Pub Employees Retirement Of Ohio, Ohio-based fund reported 7,155 shares. Northwestern Mutual Wealth owns 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 87 shares. Public Employees Retirement Association Of Colorado holds 0% or 4,224 shares in its portfolio. Huntington Bankshares holds 0% or 50 shares in its portfolio. Geode Cap Management Ltd Co holds 159,666 shares. Swiss Fincl Bank owns 29,200 shares for 0% of their portfolio.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.95 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Analysts await NetScout Systems, Inc. (NASDAQ:NTCT) to report earnings on May, 3. They expect $0.27 earnings per share, down 53.45% or $0.31 from last year’s $0.58 per share. NTCT’s profit will be $23.56M for 25.60 P/E if the $0.27 EPS becomes a reality. After $0.59 actual earnings per share reported by NetScout Systems, Inc. for the previous quarter, Wall Street now forecasts -54.24% negative EPS growth.

Since February 2, 2018, it had 0 buys, and 2 selling transactions for $225,440 activity. The insider SZABADOS MICHAEL sold $140,830. $84,610 worth of NetScout Systems, Inc. (NASDAQ:NTCT) shares were sold by DOWNING JOHN.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart